BPA for halobetasol and tazaroten
Ended Awarded Last action
- Contract number
- 36E79724A0017
- Awardee
-
Mayne Pharma Commercial LLC UEI EJMTUZC46YN3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $5,216,518.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Davis-Bacon Act FAR subpart 22.4
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement, awarded on May 29, 2024, to Mayne Pharma Commercial LLC with an ultimate completion date of December 16, 2025, establishes a single-award, non-set-aside vehicle for the supply of pharmaceutical products. The contract, valued at approximately $5.2 million, specifically covers halobetasol and tazaroten, both topical dermatological medications. Halobetasol is a potent corticosteroid used for treating inflammatory skin conditions, while tazaroten is a retinoid indicated for psoriasis and acne treatment. The agreement operates under the Federal Supply Schedule (FSS) Pharmaceuticals and Drugs schedule (61-IB), which establishes the regulatory and pricing framework for pharmaceutical procurement across federal civilian agencies. The National Acquisition Center, the civilian federal agency providing funding, utilizes this BPA to streamline procurement processes and ensure consistent availability of these essential pharmaceutical products.
The BPA structure allows the National Acquisition Center to issue task orders against the established ceiling value, enabling efficient procurement of these pharmaceutical products as operational needs arise. Mayne Pharma Commercial LLC, identified by Unique Entity Identifier EJMTUZC46YN3, serves as the primary vendor responsible for fulfilling all ordering requirements under the agreement's terms. It should be noted that the contract description indicates a BPA cancellation notation, which may reflect contract modification activities or administrative status updates during the agreement's performance period. This vehicle provides the federal civilian agency with a pre-negotiated source for critical pharmaceutical supplies, reducing procurement lead times while maintaining cost controls through the established ceiling value and Federal Supply Schedule pricing framework.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0017?
36E79724A0017 was awarded to Mayne Pharma Commercial LLC by National Acquisition Center (Headquarters) on May 29, 2024.
How much is contract 36E79724A0017 worth?
36E79724A0017's own ceiling is $5,216,518.
Who can order from contract 36E79724A0017?
36E79724A0017 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0017 under another contract?
Yes. 36E79724A0017 is a blanket purchase agreement under V797D50564, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0017 competed?
The extent of competition for 36E79724A0017 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV